Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lipocine Inc.LPCN · Entity 7696 | Director | June 03, 2026 | June 04, 2026 |
| PDL BIOPHARMA, INC.PDLI · Entity 143144 | VP, Business Development | January 08, 2020 | April 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lipocine Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2036-06-03 | Direct | 8,938 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 1,764 · Balance 8,938 F1: 100% vesting one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% vesting one year from date of grant.
PDL BIOPHARMA, INC.
Report date January 08, 2020 · Filed April 07, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 194,805 |
Reported balance
After 2020-01-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-01-08 · Grant · Acquired 194,805 · Balance 194,805 F1: The restricted stock units will vest as follows: (a) 40% of the shares subject to the award shall vest on the one year anniversary of the grant date and (b) 2.5% of the shares subject to the award shall vest monthly thereafter; provided that recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units will vest as follows: (a) 40% of the shares subject to the award shall vest on the one year anniversary of the grant date and (b) 2.5% of the shares subject to the award shall vest monthly thereafter; provided that recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:05 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 1,764 | $2.19 Strike: $2.19 | $3,863.16 |
DisclosureSEC source: 0001493152-26-027261 · ownership.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,938 Underlying: Common Stock · 1,764 shares Expires 2036-06-03 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:06 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 1,764 | $3.20 Strike: $3.20 | $5,644.80 |
DisclosureSEC source: 0001641172-25-013795 · ownership.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,174 Underlying: Common Stock · 1,764 shares Expires 2035-06-04 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:43 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 1,764 | $7.05 Strike: $7.05 | $12,436.20 |
DisclosureSEC source: 0001493152-24-023211 · ownership.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,410 Underlying: Common Stock · 1,764 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:34 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.27 Strike: $0.27 | $7,968.00 |
DisclosureSEC source: 0001493152-23-016685 · ownership.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 15:32 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.92 Strike: $0.92 | $20,240.00 |
DisclosureSEC source: 0001493152-22-016399 · ownership.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: (1) 100% vesting one year from date of grant. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 20:57 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.16 Strike: $1.16 | $11,600.00 |
DisclosureSEC source: 0001493152-22-009716 · ownership.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-11 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of April 11, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 23:36 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 194,805 | $0.00 | $0.00 |
DisclosureSEC source: 0000882104-20-000005 · wf-form4_157869934395847.xml · nonDerivative · entry 1 Jene Jill M. · CIK 0001742105 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,805 F1 · shares: The restricted stock units will vest as follows: (a) 40% of the shares subject to the award shall vest on the one year anniversary of the grant date and (b) 2.5% of the shares subject to the award shall vest monthly thereafter; provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance and retention plans covering the participant. Read SEC document |
| January 08, 2020 Filed Apr 7, 2020 12:46 UTC Amendment | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 194,805 | $0.00 | $0.00 |
DisclosureSEC source: 0000882104-20-000045 · wf-form4a_158626360070465.xml · nonDerivative · entry 1 Jene Jill M. · CIK 0001742105 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,805 F1 · shares: The restricted stock units will vest as follows: (a) 40% of the shares subject to the award shall vest on the one year anniversary of the grant date and (b) 2.5% of the shares subject to the award shall vest monthly thereafter; provided that recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 21:12 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 377,358 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0000882104-19-000026 · wf-form4_155415316311719.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,358 Underlying: Common stock · 377,358 shares Expires 2029-03-28 F1 · derivative.exercise_date: The stock options will vest as follows: (a) 25% of the shares subject to the option shall vest on the one year anniversary of January 1, 2019 and (b) 75% of the shares subject to the option shall vest on a monthly basis pro rata over the thirty-six (36) months following the one year anniversary of January 1, 2019, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance agreement between the issuer and the recipient. Read SEC document |
| March 28, 2019 Filed Apr 16, 2019 21:18 UTC Amendment | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 384,615 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0000882104-19-000041 · wf-form4a_155544946729502.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,615 Underlying: Common stock · 384,615 shares Expires 2029-03-28 F1 · shares: The number of shares included in the original April 1, 2019 Form 4 filing was incorrect and the Company is filing this amendment to correct the number of shares in the award grant. F2 · derivative.exercise_date: The stock options will vest as follows: (a) 25% of the shares subject to the option shall vest on the one year anniversary of January 1, 2019 and (b) 75% of the shares subject to the option shall vest on a monthly basis pro rata over the thirty-six (36) months following the one year anniversary of January 1, 2019, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance agreement between the issuer and the recipient. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 20:40 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 377,358 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0000882104-18-000102 · wf-form4_153808078828040.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,358 Underlying: Common stock · 377,358 shares Expires 2028-09-25 F1 · derivative.exercise_date: The stock options will vest on a monthly basis pro rata over the 48 months following January 1, 2018, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance agreement between the issuer and the recipient. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.